[1]TESTA;FONTANELLA[Farmaco,EdizioneScientifica,1965,vol.20,p.323-335]
[1]CurrentPatentAssignee:NEUROCRINEBIOSCIENCESINC-WO2008/124614,2008,A1Locationinpatent:Page/Pagecolumn42-43
[2]TESTA;FONTANELLA[Farmaco,EdizioneScientifica,1965,vol.20,p.323-335]
[3]CurrentPatentAssignee:BRISTOL-MYERSSQUIBBCO-US2002/173503,2002,A1
[4]CurrentPatentAssignee:BRISTOL-MYERSSQUIBBCO-US2004/186094,2004,A1
[5]CurrentPatentAssignee:BRISTOL-MYERSSQUIBBCO-US6849619,2005,B2
[6]CurrentPatentAssignee:COCRYSTALPHARMA,INC.-WO2021/188620,2021,A1Locationinpatent:Paragraph00215;00446-00447
[1]TESTA;FONTANELLA[Farmaco,EdizioneScientifica,1965,vol.20,p.323-335]
[1]TESTA;FONTANELLA[Farmaco,EdizioneScientifica,1965,vol.20,p.323-335]
[1]TESTA;FONTANELLA[Farmaco,EdizioneScientifica,1965,vol.20,p.323-335]
Title: Towards discovering dual functional inhibitors against both wild type and K103N mutant HIV-1 reverse transcriptases: molecular docking and QSAR studies on 4,1-benzoxazepinone analogues.
Journal: Journal of computer-aided molecular design 20060501
Title: 4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20010604